Edition:
United States

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

13.05USD
15 Dec 2017
Change (% chg)

$-0.30 (-2.25%)
Prev Close
$13.35
Open
$13.20
Day's High
$13.45
Day's Low
$12.75
Volume
1,002,837
Avg. Vol
--
52-wk High
$15.40
52-wk Low
$12.51

Latest Key Developments (Source: Significant Developments)

Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc
Tuesday, 21 Nov 2017 04:58pm EST 

Nov 21 (Reuters) - Apellis Pharmaceuticals Inc :Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing.  Full Article

Apellis Pharmaceuticals announces closing of its IPO
Monday, 13 Nov 2017 04:05pm EST 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::Apellis pharmaceuticals announces closing of its initial public offering.  Full Article

Apellis Pharma shares debut about 3.6 pct above IPO price
Thursday, 9 Nov 2017 10:13am EST 

Nov 9 (Reuters) - :Apellis Pharmaceuticals Inc shares open at $14.50 in debut on the NASDAQ versus IPO price of $14 per share‍​.  Full Article

Apellis prices IPO of 10.7 mln common shares at $14/shr
Wednesday, 8 Nov 2017 09:38pm EST 

Nov 9 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals announces pricing of initial public offering.Says initial public offering of 10.7 million common shares priced at $14.00 per share.  Full Article

Apellis Pharmaceuticals sees IPO of 10.71 mln shares‍​ of common stock
Monday, 30 Oct 2017 10:50am EDT 

Oct 30 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals Inc sees IPO of 10.71 million shares‍​ of common stock to be priced between $13.00 and $15.00 per share - sec filing.  Full Article

Apellis Pharma adds Evercore ISI as IPO underwriter
Friday, 20 Oct 2017 06:00pm EDT 

Oct 20 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals Inc says it adds Evercore ISI to underwriters to the IPO - SEC filing‍​.  Full Article

Apellis announces FDA fast track designation for APL-2 in PNH
Tuesday, 20 Dec 2016 08:00am EST 

Apellis Pharmaceuticals Inc :Apellis announces fda fast track designation for apl-2 in pnh.  Full Article

Apellis to present safety and efficacy data from clinical trials of APL-2 in pnh at December scientific meetings
Monday, 21 Nov 2016 08:00am EST 

Apellis Pharmaceuticals Inc :Apellis to present safety and efficacy data from clinical trials of APL-2 in pnh at December scientific meetings.  Full Article

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)